» Articles » PMID: 18056685

Effect of Apolipoprotein A-V on Plasma Triglyceride, Lipoprotein Size, and Composition in Genetically Engineered Mice

Overview
Journal J Lipid Res
Publisher Elsevier
Specialty Biochemistry
Date 2007 Dec 7
PMID 18056685
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Transgenic (Tg) mice that overexpress the human apolipoprotein A-V gene (APOA5) yet lack an endogenous mouse apoa5 gene (APOA5 Tg mice) were generated. Subsequently, the effect of human apoA-V expression on plasma triglyceride (TG) concentration and lipoprotein and apolipoprotein distribution was determined and compared with that in mice deficient in apoA-V (apoa5(-/-) mice). NMR analysis of plasma lipoproteins revealed that APOA5 Tg mice had a very low VLDL concentration (26.4 +/- 7.7 nmol/dl), whereas VLDL in apoa5(-/-) mice was 18- fold higher (467 +/- 152 nmol/dl). SDS-PAGE analysis of the d < 1.063 g/ml plasma fraction revealed that the apoB-100/apoB-48 ratio was 14-fold higher in APOA5 Tg versus apoa5(-/-) mice and that the apoE/total apoB ratio was 7-fold greater in APOA5 Tg versus apoa5(-/-) mice. It is anticipated that a reduction in apoB-100/apoB-48 ratio as well as that for apoE/apoB would impair the uptake of VLDL and remnants in apoa5(-/-) mice, thereby contributing to increased plasma TG levels. The concentration of apoA-V in APOA5 Tg mice was 12.5 +/- 2.9 microg/ml, which is approximately 50- to 100-fold higher than that reported for normolipidemic humans. ApoA-V was predominantly associated with HDL but was rapidly and efficiently redistributed to apoA- V-deficient VLDL upon incubation. Consistent with findings reported for human subjects, apoA-V concentration was positively correlated with TG levels in normolipidemic APOA5 Tg mice. It is conceivable that, in a situation in which apoA-V is chronically overexpressed, complex interactions among factors regulating TG homeostasis may result in a positive correlation of apoA-V with TG concentrations.

Citing Articles

Hypertriglyceridemia in Apoa5-/- mice results from reduced amounts of lipoprotein lipase in the capillary lumen.

Yang Y, Beigneux A, Song W, Nguyen L, Jung H, Tu Y J Clin Invest. 2023; 133(23).

PMID: 37824203 PMC: 10688983. DOI: 10.1172/JCI172600.


Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine.

Huang P, Zhu W, Xiao J, Zhang Y, Li R, Yang Y Front Pharmacol. 2022; 13:935362.

PMID: 36034782 PMC: 9411997. DOI: 10.3389/fphar.2022.935362.


An anti-ANGPTL3/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif.

Balasubramaniam D, Schroeder O, Russell A, Fitchett J, Austin A, Beyer T J Lipid Res. 2022; 63(5):100198.

PMID: 35307397 PMC: 9036128. DOI: 10.1016/j.jlr.2022.100198.


Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models.

Basu D, Bornfeldt K Front Endocrinol (Lausanne). 2020; 11:504.

PMID: 32849290 PMC: 7423973. DOI: 10.3389/fendo.2020.00504.


Emerging evidences for the opposite role of apolipoprotein C3 and apolipoprotein A5 in lipid metabolism and coronary artery disease.

Dai W, Zhang Z, Yao C, Zhao S Lipids Health Dis. 2019; 18(1):220.

PMID: 31836003 PMC: 6909560. DOI: 10.1186/s12944-019-1166-5.